Volume 14, Issue 5 (Dec & Jan 2021)
payavard 2021, 14(5): 465-475 |
Back to browse issues page
Ethics code: IR.TUMS.SPH.REC.1399.021
Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
Safdari R, Naser Moghadasi A, Khenarinezhad S, GhazanfariSavadkoohi E. Development, and evaluation of drug monitoring system for multiple sclerosis patients. payavard 2021; 14 (5) :465-475
URL: http://payavard.tums.ac.ir/article-1-7009-en.html
URL: http://payavard.tums.ac.ir/article-1-7009-en.html
1- Professor, Department of Health Information Management, School of Allied Medical Sciences, Tehran University of Medical Sciences, Tehran, Iran
2- Assistant Professor, Department of Neurology, Multiple Sclerosis Research Center, Neuroscience Institute, Tehran University of Medical Sciences, Tehran, Iran
3- Master of Science in Health Information Technology, School of Allied Medical Sciences, Mazandaran University of Medical Sciences, Sari, Iran
4- Master of Science in Health Information Technology, School of Allied Medical Sciences, Tehran University of Medical Sciences, Tehran, Iran , ghazanfarisavadkoohi@gmail.com
2- Assistant Professor, Department of Neurology, Multiple Sclerosis Research Center, Neuroscience Institute, Tehran University of Medical Sciences, Tehran, Iran
3- Master of Science in Health Information Technology, School of Allied Medical Sciences, Mazandaran University of Medical Sciences, Sari, Iran
4- Master of Science in Health Information Technology, School of Allied Medical Sciences, Tehran University of Medical Sciences, Tehran, Iran , ghazanfarisavadkoohi@gmail.com
Abstract: (1492 Views)
Background and Aim: Taking a wide range of medications in Multiple sclerosis (MS) patients can lead to side effects and drug interactions. Therefore, the use of intelligent systems such as drug monitoring systems can help in the effective and timely treatment of MS disease. In this regard, the present study was conducted to design, development, and evaluation of the drug monitoring system for multiple sclerosis patients.
Materials and Methods: The present descriptive-developmental study was performed in four stages. In the first stage, by searching the library resources and valid guidelines, the minimum data set was determined and provided to neurologists and MS fellowships in the form of checklists for validation. Then the software was designed logically and coded based on the opinion of experts. In the last stage, the software was evaluated by end-users.
Results: The information elements in the software design were categorized into patient demographic information, medical history, clinical signs, imaging procedures, laboratory tests for ocrelizumab and fingolimod drugs, counseling, and treatment data. Finally, the performance of the drug monitoring system was evaluated with an average of 7.9 and was approved by users.
Conclusion: The results of software evaluation showed that the drug monitoring system can help general practitioners, neurologists, and MS fellowships in monitoring and follow-up of patients and lead to increased patient safety.
Materials and Methods: The present descriptive-developmental study was performed in four stages. In the first stage, by searching the library resources and valid guidelines, the minimum data set was determined and provided to neurologists and MS fellowships in the form of checklists for validation. Then the software was designed logically and coded based on the opinion of experts. In the last stage, the software was evaluated by end-users.
Results: The information elements in the software design were categorized into patient demographic information, medical history, clinical signs, imaging procedures, laboratory tests for ocrelizumab and fingolimod drugs, counseling, and treatment data. Finally, the performance of the drug monitoring system was evaluated with an average of 7.9 and was approved by users.
Conclusion: The results of software evaluation showed that the drug monitoring system can help general practitioners, neurologists, and MS fellowships in monitoring and follow-up of patients and lead to increased patient safety.
Send email to the article author
| Rights and permissions | |
 |
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License. |
